Ulcerative colitis

A newly FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderately to severely active Crohn's disease another targeted treatment option. It's the same IL-23–targeting drug already approved for ulcerative...

A new FDA approval means an additional biologic treatment option for adults with moderate to severe Crohn's disease. This may affect treatment choices and insurance coverage discussions for people with IBD.

This expands U.S. treatment options: Omvoh (mirikizumab) is now FDA‑approved for both major forms of IBD (ulcerative colitis and Crohn's disease), which may matter for people who haven’t responded to other therapies. The...

At‑home tests that claim to identify food triggers for IBS or related gut conditions may influence how people manage symptoms. Patents covering tests for Crohn’s and ulcerative colitis suggest the company is aiming to...

Clinical trials expand treatment options and are how new IBD therapies are tested and approved. Low enrollment can delay access to future treatments for Crohn’s and ulcerative colitis.

Clinical trials are how new treatments become available, so participation and awareness can directly affect treatment options for people with Crohn’s disease and ulcerative colitis. The article also highlights that...

Skin disease (hidradenitis suppurativa) may be more common in people with IBD—particularly Crohn disease—and could be linked with more severe intestinal complications. Awareness can prompt coordinated care between...

The review brings together evidence that genetics, immune responses, the gut microbiome, and environmental triggers interact to cause Crohn's disease and ulcerative colitis.

After a Crohn’s or UC flare you may tolerate less fiber and need easy-to-digest foods and extra protein to support recovery. This article gives practical, food-based suggestions to help with nutrient intake while your...

Fatigue is common in people with Crohn’s disease and ulcerative colitis and can persist even when standard measures say the disease is in remission. This study suggests stricter definitions of remission don’t necessarily...

This notes a new oral investigational drug (Amelenodor/NX-13) in Phase I for Crohn’s and ulcerative colitis and highlights industry predictions about its chances of advancing. People with IBD may want to know about...

Seeing well-known people talk about IBD or IBS can reduce stigma and show that these conditions affect many kinds of people, including athletes and performers. The article may help patients feel less alone and point to...